{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/prostate-cancer/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"d95f0cd5-43fd-5950-b45a-5d312e16b3e3","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field 346b2101-3882-441a-a6c3-73e76f18ccef --><h2>Changes</h2><!-- end field 346b2101-3882-441a-a6c3-73e76f18ccef -->","summary":null,"htmlStringContent":"<!-- begin item b083fb9c-2449-480a-9d29-5763e51abb53 --><!-- begin field 4a6e9459-c1e1-4136-a82b-de3fe12d2561 --><p><strong>February 2021 </strong>— minor update. Clarification of wording in PSA referral for men aged 50-69. </p><p><strong>October 2017</strong> — minor update. Changes made to age ranges in interpreting PSA results section to reflect PHE and UK National Screening Committee guidance. </p><p><strong>July to August 2017</strong> — reviewed. A literature search was conducted in August 2017 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of the topic. Structural changes have been made to this topic, and recommendations on prostate-specific antigen (PSA) testing and treatments for prostate cancer have been updated in line with the latest National Institute for Health and Care Excellence (NICE) guidance.</p><!-- end field 4a6e9459-c1e1-4136-a82b-de3fe12d2561 --><!-- end item b083fb9c-2449-480a-9d29-5763e51abb53 -->","topic":{"id":"2ab521f2-aa56-5e1e-b28e-fc4d637a303c","topicId":"1506c25e-8998-42e4-82c0-6b38dc3a1e9f","topicName":"Prostate cancer","slug":"prostate-cancer","lastRevised":"Last revised in October 2017","chapters":[{"id":"324faedd-14d8-5d99-8059-d9428da432ea","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"276607b5-8522-5d5e-86f1-d9be97d83a94","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"df8fe922-4f04-5594-b4a9-fc0935cf3b16","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"d95f0cd5-43fd-5950-b45a-5d312e16b3e3","slug":"changes","fullItemName":"Changes"},{"id":"dc0f462f-4d9f-503f-ae6e-64aa386af1e8","slug":"update","fullItemName":"Update"}]},{"id":"fb4bea73-b877-5f11-9f5e-f4b1a776c6ab","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"d9df68e4-4518-5224-b388-b610695e181f","slug":"goals","fullItemName":"Goals"},{"id":"cbda6200-7ae0-5f80-b984-4f2e0d78d4de","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"b6c612ea-8423-5c36-abab-32784d6ed762","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"4909e587-a937-5829-873f-b3e02e5c8a36","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"b3baf3db-45b6-5fd4-94e3-cbbaf8d70bd9","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"d0703c17-2896-5c8e-a091-a6024da2508d","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"b6a5e49a-643a-5e4a-a980-dc835d73c66d","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"7fb66c84-18e5-52f1-b7ef-daf96c4f903c","slug":"definition","fullItemName":"Definition"},{"id":"ae301838-d2bd-55ed-a057-844f73f6942a","slug":"causes","fullItemName":"Causes"},{"id":"5656e958-479a-5103-96a1-2b0d6c62c156","slug":"prevalence","fullItemName":"Prevalence"},{"id":"49f9ec22-1376-50e7-8891-e6050fbb5069","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"cf644b3b-5878-59e9-9641-63847a7f0cb5","slug":"prognosis","fullItemName":"Prognosis"},{"id":"511452bc-068d-5f51-b489-9e89b4396cd2","slug":"complications","fullItemName":"Complications"}]},{"id":"6c4ca641-81fa-53e0-8562-431396232bd7","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"7e53b66c-2f4f-500c-a8c0-9092cbce65bf","slug":"overview","fullItemName":"Overview"},{"id":"5e184056-05a4-5462-80be-51f03c9c94a2","slug":"signs-symptoms","fullItemName":"Signs and symptoms"},{"id":"5f6622b7-59bf-51f5-b413-1f0ec1a4b8d1","slug":"psa-testing","fullItemName":"PSA testing"},{"id":"30dc380e-addd-57b7-a015-a1b250c58b3c","slug":"digital-rectal-examination","fullItemName":"Digital rectal examination"},{"id":"509e34cf-6a18-526e-a3f0-d219fa4030de","slug":"when-to-refer","fullItemName":"When to refer"},{"id":"8fdd4166-47a6-5d1b-b573-bb1ab5d09da8","slug":"confirming-diagnosis-in-secondary-care","fullItemName":"Confirming diagnosis in secondary care"}]},{"id":"9dc72b4c-cd09-5f23-b45c-6d0306fa66dc","fullItemName":"Management","slug":"management","subChapters":[{"id":"56e2a92b-f611-57ed-91c6-f6672b72750f","slug":"management","fullItemName":"Scenario: Management"},{"id":"6cf2bc9c-e41d-5e71-b490-a48c7fa4a38b","slug":"complications-adverse-effects","fullItemName":"Scenario: Complications and adverse effects"}]},{"id":"742a5289-99d4-5d61-a8c9-7fc8409f0f23","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"5009abfd-1456-55b3-844d-23b74552f90c","slug":"medroxyprogesterone-acetate","fullItemName":"Medroxyprogesterone acetate"},{"id":"80712d44-9544-56aa-aa10-d4cd640429de","slug":"cyproterone-acetate","fullItemName":"Cyproterone acetate"}]},{"id":"7bed120a-c6b8-5f7e-941d-751749f78c0e","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"1c5c0083-b591-5115-8039-cdc5113cc070","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"6562ed52-3498-5877-b63d-7bb4a7b2656a","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"e27e1bd1-e689-5a6c-a6e5-36b9fcad98a3","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"1d7864fd-9f5c-5976-a1b8-9df023b04f7e","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"e6798a57-1676-5675-b1a1-50a69534adff","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"67b2f477-e9ac-5da3-a8ab-5544ec9d70f3","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"812bede6-3d25-5e1d-ba87-ac56af0e611f","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"df8fe922-4f04-5594-b4a9-fc0935cf3b16","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"dc9f5a50-1145-51c1-8f5c-bb4ae1ffc7a0","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"","summary":null,"htmlStringContent":"<!-- begin item 25f69012-9555-4952-a17f-a7b700757710 --><!-- begin field 9e418b77-7ea7-4c4e-a49d-a7b700757cf4 -->Previous changes<!-- end field 9e418b77-7ea7-4c4e-a49d-a7b700757cf4 --><!-- begin field 484f3daa-1dd3-4aaf-989b-a7b700757cf4 --><p><strong>November 2016 </strong>—<strong> </strong>minor update. The National Institute for Health and Care Excellence (NICE) quality standards for suspected cancer have been added to this topic.</p><p><strong>May 2014 </strong>— minor update. The word prescriptions has been removed from the section on suspected spinal cord compression.</p><p><strong>December 2013 </strong>— minor update. Broken link to Prosdex option grid fixed.</p><p><strong>May 2013 </strong>— minor update. References to the Prostate Cancer Charity and all relevant links have been updated to Prostate Cancer UK. Duplicate links have also been removed.</p><p><strong>March 2013 </strong>— minor update. The telephone number for NHS Direct has been updated.</p><p><strong>January 2011 </strong>— minor correction of information about degarelix.</p><p><strong>October 2010 to January 2011 </strong>— this is a new CKS topic. The evidence-base has been reviewed in detail, and recommendations are clearly justified and transparently linked to the supporting evidence.</p><!-- end field 484f3daa-1dd3-4aaf-989b-a7b700757cf4 --><!-- end item 25f69012-9555-4952-a17f-a7b700757710 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}